450.137 Access to investigational drugs, devices, and biological products for terminally ill patients.

394 words·~2 min read·/wi/chapter-450/450-137-2

A research copy — for the controlling text, always check the official state or federal source. Not legal advice.

(1)Definitions. In this section:

(a)“Eligible patient” means a patient who is eligible under sub.

(2).

(b)“Investigational drug, device, or biological product” means a drug, device, or biological product that has not been approved or licensed for use by the federal food and drug administration and meets all of the following conditions:

1. The drug, device, or biological product has successfully completed a phase one clinical trial approved by the federal food and drug administration.

2. The drug, device, or biological product remains under investigation in a phase 2 or 3 clinical trial approved by the federal food and drug administration or has completed a phase 3 clinical trial and is pending approval or licensure by the federal food and drug administration.

3. The active development or production of the drug, device, or biological product is ongoing and has not been discontinued by the manufacturer or placed on clinical hold under 21 USC 355 (i).

(c)“Life-threatening disease or condition” means a disease or condition that is life-threatening, as defined in 21 CFR 312.81

(a).

(2)Eligibility. An individual is an eligible patient for purposes of this section if the individual meets all of the following conditions:

(a)Has been diagnosed with a life-threatening disease or condition.

(b)Has exhausted approved treatment options and is unable to participate in a clinical trial involving the investigational drug, device, or biological product.

(c)Has received a recommendation or prescription order from the individual’s treating physician for an investigational drug, device, or biological product.

(d)Has given written informed consent to use the investigational drug, device, or biological product. The content of the written informed consent provided by the patient shall be consistent with and at least as comprehensive as the consent used in clinical trials for the investigational drug, device, or biological product.

(e)Is aware of the potential costs that may be associated with or otherwise result from the use of the investigational drug, device, or biological product under this section.

(f)Possesses a written verification executed by the individual’s treating physician attesting that the individual meets the conditions under pars.

(a)to

(e), and that the physician is not compensated directly by the manufacturer of the investigational drug, device, or biological product for making that attestation.